Peptomyc Appoints Selwyn Ho to its Board of Directors

Peptomyc S.L., a clinical stage company specialized in the development of protein therapeutics targeting the MYC oncoprotein for cancer treatment, today announced the appointment of Dr. Selwyn Ho, MB, BS, to its Board of Directors.   Read more

MYC targeting by OMO-103 in solid tumors: a phase 1 trial

Peptomyc presents results of their Ph1 study of OMO-103 in advanced solid tumours. OMO-103 is an inhibitor for MYC, one of the most wanted, long-considered, undruggable oncogenes. The trial has established the safety, tolerability and pharmacokinetic profile of OMO-103, advising on Ph2 design and identifying soluble factors with the potential as pharmacodynamic and predictive response […]

Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial

Peptomyc is proud to announce that the results of the MYCure clinical trial have just been published in Nature Medicine (, demonstrating the unique potential of our lead first-in-class MYC inhibitor, OMO-103, to treat multiple oncological indications. Peptomyc takes pride in pioneering the blockade of a most-wanted target in cancer, and we believe this encouraging […]

Aliath Bioventures appoints Dr Philippe Monteyne and announces additional hires to further strengthen its Life Sciences Impact business

Aliath Bioventures, the healthcare impact investment platform of AltamarCAM Partners, appoints Philippe Monteyne, MD, PhD as a new Partner to reinforce the company’s healthcare investment team. As of 16th November 2023, Philippe Monteyne will join the team responsible for Alta Life Sciences Spain I FCR and the newly launched, ACP Aliath Bioventures II FCR (ABV […]

New appointment

Delighted to have Pamela Klein join the board of one of the companies of Alta Life Sciences Spain I FCR. Read more